Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian A Walker

Showing results (71-80 of 137) with videos related to

Pageof 14
Sort By:
Blood Cancer Journal|May 31, 2022
Structural variants shape the genomic landscape and clinical outcome of multiple myelomaCody Ashby, Eileen M Boyle, Michael A Bauer, et al.
Oncotarget|February 19, 2019
Poor overall survival in hyperhaploid multiple myeloma is defined by double-hit bi-allelic inactivation of <i>TP53</i>Cody Ashby, Ruslana G Tytarenko, Yan Wang, et al.
Blood Advances|October 15, 2025
Diagnostic sequencing identifies high-risk markers and mechanisms of resistance to guide immunotherapy selectionParvathi Sudha, Phillip Pham, Wen Niu, et al.
Nature Communications|August 3, 2022
The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory statesLeo Rasche, Carolina Schinke, Francesco Maura, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 20, 2011
Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myelomaDavid C Johnson, Sophie L Corthals, Brian A Walker, et al.
Oncotarget|April 22, 2017
The varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myelomaCaleb K Stein, Charlotte Pawlyn, Shweta Chavan, et al.
Cancer Immunology Research|May 8, 2025
Identification of the distinct immune microenvironment features associated with progression following high dose melphalan and autologous stem cell transplant in multiple myelomaParvathi Sudha, Travis S Johnson, Habib Hamidi, et al.
Haematologica|May 28, 2017
The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myelomaAneta Mikulasova, Christopher P Wardell, Alexander Murison, et al.
Seminars in Cell & Developmental Biology|May 7, 2021
Chromothripsis as a pathogenic driver of multiple myelomaFrancesco Maura, Eileen M Boyle, Even H Rustad, et al.
Genes, Chromosomes & Cancer|October 1, 2011
The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapyKevin D Boyd, Fiona M Ross, William J Tapper, et al.
Pageof 14

Showing results (71-80 of 137) with videos related to

Sort By:
Pageof 14
Blood Cancer Journal|May 31, 2022
Structural variants shape the genomic landscape and clinical outcome of multiple myelomaCody Ashby, Eileen M Boyle, Michael A Bauer, et al.
Oncotarget|February 19, 2019
Poor overall survival in hyperhaploid multiple myeloma is defined by double-hit bi-allelic inactivation of <i>TP53</i>Cody Ashby, Ruslana G Tytarenko, Yan Wang, et al.
Blood Advances|October 15, 2025
Diagnostic sequencing identifies high-risk markers and mechanisms of resistance to guide immunotherapy selectionParvathi Sudha, Phillip Pham, Wen Niu, et al.
Nature Communications|August 3, 2022
The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory statesLeo Rasche, Carolina Schinke, Francesco Maura, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 20, 2011
Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myelomaDavid C Johnson, Sophie L Corthals, Brian A Walker, et al.
Oncotarget|April 22, 2017
The varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myelomaCaleb K Stein, Charlotte Pawlyn, Shweta Chavan, et al.
Cancer Immunology Research|May 8, 2025
Identification of the distinct immune microenvironment features associated with progression following high dose melphalan and autologous stem cell transplant in multiple myelomaParvathi Sudha, Travis S Johnson, Habib Hamidi, et al.
Haematologica|May 28, 2017
The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myelomaAneta Mikulasova, Christopher P Wardell, Alexander Murison, et al.
Seminars in Cell & Developmental Biology|May 7, 2021
Chromothripsis as a pathogenic driver of multiple myelomaFrancesco Maura, Eileen M Boyle, Even H Rustad, et al.
Genes, Chromosomes & Cancer|October 1, 2011
The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapyKevin D Boyd, Fiona M Ross, William J Tapper, et al.
Pageof 14